This Specialty Chemical Stock is Set to Make History with its First-Ever Stock Split

A stock price can theoretically rise indefinitely, as there is no upper limit to how high it can go. The key driver behind a stock's long-term growth is the performance and profitability of the underlying business.

For instance, companies like MRF have seen their stock prices surge due to consistent earnings growth and market leadership.

However, when stock prices become exceptionally high, they can discourage participation from retail investors who may not find them accessible.

To counter this, companies often conduct stock splits, dividing shares into smaller units to enhance liquidity while maintaining the same overall market capitalisation.

One such company preparing for a stock split is IOL Chemicals.

• IOL Chemicals and Pharmaceuticals announced stock split in December 2024. The split was approved by shareholders in a postal ballot on 31 January 2025.
• The company has announced a stock split in the ratio of 1:5. This means the sub-division of the existing 1 equity share of the face value of Rs 10 each fully paid up into 5 equity shares of the face value of Rs 2 each fully paid up.
• The record date to determine the eligibility of shareholders for the stock split is 11 March 2025.
• This is the first time in the company's trading history that it has announced such a corporate action. While IOL Chemicals has issued dividends in the past, it has never carried out a stock split or has issued bonus shares.

Recent Developments

#1 Quetiapine Fumarate Certification

IOL Chemicals and Pharmaceuticals Ltd. has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its API product, Quetiapine Fumarate.

This certification allows the company to export the drug to European countries and other regions that recognize CEPs, expanding its global market reach.

Quetiapine Fumarate is an antipsychotic medication widely used for treating mental health disorders such as schizophrenia and bipolar disorder.

This milestone strengthens IOL Chemicals' position in the pharmaceutical API segment, reinforcing its commitment to quality and regulatory compliance.

#2 Responsible Care^® Certification

On 25 December 2024, IOL Chemicals and Pharmaceuticals Ltd. was awarded the Responsible Care^® label by the Indian Chemical Council (ICC) for a three-year term, becoming the 100th company to receive this recognition.

The certification authorises the company to use the Responsible Care (RC) logo, reflecting its adherence to the highest standards of safety, environmental responsibility, and ethical business practices.

The Responsible Care initiative ensures that chemicals are handled safely at every stage of their life cycle while promoting sustainability and improving quality of life.

This recognition highlights IOL Chemicals' ongoing efforts to prioritize safety and sustainability across its operations.

A Close Look at Financials

For the December 2024 quarter, the company's net sales increased marginally by 0.6% YoY to Rs 5,233 m.

Its net profit declined 11% to Rs 205.3 m in the December 2024 quarter from Rs 230.8 m in the same quarter a year ago.

IOL Chemical's Financial Snapshot (FY20-24)

(Rs m, Consolidated)	FY20	FY21	FY22	FY23	FY24
Net sales	18,945	19,670	21,840	22,171	21,328
Sales Growth (%)	12.4	3.8	11	1.5	(-3.8)
Net Profit	3,613	4,446	1,677	1,391	1,344
Net Profit Margin (%)	19.1	22.6	7.7	6.3	6.3
Return on Equity (%)	44.9	35.3	12	9.2	8.3

Source: Equitymaster

Its revenue saw a CAGR growth of 4.8%, over the last five years. The company's profitability has declined over years.

In terms of return ratios, the company's five-year average ROE is 22%.

What Next?

Moving forward, IOL Chemicals and Pharmaceuticals Ltd. aims to expand its global footprint by strengthening partnerships with leading pharmaceutical companies and enhancing its portfolio of high-quality API products.

The company plans to invest in advanced research and innovation to develop next-generation generics, catering to the rising demand for essential and specialized medicines.

With a strong focus on therapeutic areas such as pain management, central nervous system disorders, anti-allergic treatments, and lifestyle-related diseases like cardiovascular conditions and diabetes.

How Shares of IOL Chemicals have Performed Recently

The share price of IOL Chemicals has climbed 11% in the past 5 days. However, it's down 10% over the last month.

Over the past year, the company's shares have declined 13%.

The company touched its 52-week high of Rs 537.1 on 16 September 2024 and its 52-week low of Rs 293.5 on 3 March 2025.

About IOL Chemicals

IOL Chemicals and Pharmaceuticals Ltd. is a leading API manufacturer and a prominent player in India's specialty chemicals industry.

The company has a strong foothold in key therapeutic segments, including pain management, anticonvulsants, anti-diabetes, anti-cholesterol, and anti-platelet treatments.

Its diverse product portfolio features APIs such as Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, and Paracetamol, along with specialty chemicals like Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, and Acetyl Chloride.

Notably, IOL Chemicals is the world's largest producer of Ibuprofen, boasting an installed capacity of 12,000 TPA.

With a fully backward-integrated manufacturing facility, the company ensures efficient production and consistent quality, further strengthening its leadership in the pharmaceutical and chemical sectors.

Investors should evaluate the company's fundamentals, corporate governance, and valuations of the stock as key factors when conducting due diligence before making investment decisions.

For more details, see the IOL Chemicals & Pharm. company fact sheet and quarterly results.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...